[Experiences with conversion from MC-insulin NOVO to L-insulin S.N.C. of insulin dependent diabetic patients].
After a circa 10-year therapy with MC-insulin NOVO 12 diabetics were changed to the chromatographically purified insulins L-insulin S.N.C. and insulin S.N.C. of the nationally-owned enterprise Berlin-Chemie. 3 and 6 months, respectively, ago after the ambulatory change the patients were metabolically, immunologically, hormonally and clinically characterized. Profiles of blood glucose, value of glycaemia and HbA1 also lipid parameters, creatinine values, residual B-cell function, blood pressure and ophthalmologic state did not show any significant differences to the initial values after change to S.N.C.-insulins. Insulin-antibody level (9.5%-9.4%-9.7%) and insulin need (0.48 IU/kg-0.46 IU/kg-0.48 Iu/kg) also remained unchanged. Local reactions were not observed. Under the condition of a permanently good quality of the S.N.C.-insulins (purity and stability of the preparations) the application of chromatographically purified insulin of the firm Berlin-Chemie with comparable therapeutic success as in insulin MC NOVO is possible in a large part of the patients.
Hildebrandt
R
R
Zentralstelle für Diabetes und Stoffwechselkrankheiten, Berlin.
Ziehe
H
H
Ziehe
S
S
Ratzmann
K P
KP
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D003692:Delayed-Action Preparations; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000008:administration & dosage* / Q000009:adverse effects; D061389:Insulin, Regular, Pork; D008297:Male; D008875:Middle Aged
D001786:Blood Glucose; D002096:C-Peptide; D003692:Delayed-Action Preparations; D006442:Glycated Hemoglobin; D007328:Insulin; D061389:Insulin, Regular, Pork; C000006:insulin, neutral
Erfahrungen bei der Umstellung von MC-Insulin-Präparaten NOVO auf L-Insulin S.N.C. bei insulinbehandelten Diabetikern.